CSL is the world's leading plasma-derived therapy company and one of the world's leading biotechnology companies.
CSL is the world's leading plasma-derived therapy company, with annual revenue of approximately $15 billion across CSL Behring (plasma-derived therapies), CSL Seqirus (influenza vaccines), and CSL Vifor (iron deficiency and nephrology). Headquartered in Melbourne, Australia, CSL's plasma collection network of over 300 centers globally — combined with its fractionation manufacturing infrastructure — creates one of the most formidable competitive moats in the biopharmaceutical industry. CSL Behring's immunoglobulin portfolio — encompassing HIZENTRA subcutaneous IgG, PRIVIGEN intravenous IgG, and HAEGARDA for hereditary angioedema — is the market leader across multiple plasma product categories. The integration of Vifor Pharma — acquired for $11.7 billion in 2022 — added iron deficiency and nephrology franchises.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. CSL — Key Financial Metrics 2023-2025
Table 2. CSL — Revenue by Product 2023-2025
Table 3. CSL — Revenue by Geography 2023-2025
Table 4. CSL — R&D Investment 2023-2025
Table 5. CSL — SWOT Analysis
Table 6. CSL — Key Products and Pipeline 2025
Table 7. CSL — M&A Activity 2020-2025
Table 8. CSL — Key Management 2025
Table 9. CSL — Strategic Priorities 2025-2030
